Intervention Review

Creatine for amyotrophic lateral sclerosis/motor neuron disease

  1. Daniel M Pastula1,*,
  2. Dan H Moore2,
  3. Richard S Bedlack3

Editorial Group: Cochrane Neuromuscular Group

Published Online: 12 DEC 2012

Assessed as up-to-date: 16 JUL 2012

DOI: 10.1002/14651858.CD005225.pub3


How to Cite

Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD005225. DOI: 10.1002/14651858.CD005225.pub3.

Author Information

  1. 1

    UCSF Medical Center, Neurology, San Francisco, California, USA

  2. 2

    California Pacific Medical Center, Research Institute, San Francisco, CA, USA

  3. 3

    Duke Medical Center, Division of Neurology, Durham, USA

*Daniel M Pastula, Neurology, UCSF Medical Center, UCSF Neurology, Box 0114, 505 Parnassus Ave, San Francisco, California, 94143-0114, USA. Daniel.Pastula@ucsfmedctr.org.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 12 DEC 2012

SEARCH

  1. Current Version

    Creatine for amyotrophic lateral sclerosis/motor neuron disease

    Daniel M Pastula, Dan H Moore and Richard S Bedlack

    Version of Record online: 12 DEC 2012 | DOI: 10.1002/14651858.CD005225.pub3

Previous versions of this article and their online publication dates

  1. Version 2

    Creatine for amyotrophic lateral sclerosis/motor neuron disease

    Daniel M. Pastula, Dan H Moore and Richard S Bedlack

    Version of Record online: 16 JUN 2010 | DOI: 10.1002/14651858.CD005225.pub2

  2. Version 1

    Creatine for amyotrophic lateral sclerosis/motor neuron disease

    Richard S Bedlack and Milan C Mathew

    Version of Record online: 20 APR 2005 | DOI: 10.1002/14651858.CD005225